Drug intelligence / Profile preview

loxenatide

Development stage: Phase 3
Lead developer: Hansoh Pharmaceutical Group
Modality: Peptides
Administration: Subcutaneous

Overview

Loxenatide is a short-acting glucagon-like peptide-1 (GLP-1) analog. It functions as a GLP-1 receptor agonist, stimulating intracellular insulin synthesis and secretion while inhibiting glucagon secretion, thereby exerting hypoglycemic effects. Beyond glucose regulation, loxenatide can also suppress appetite, delay gastric emptying, increase insulin sensitivity in peripheral tissues and the liver, and offer protective benefits to various organs. It is primarily developed for the treatment of Type 2 Diabetes Mellitus (T2DM).

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on loxenatide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on loxenatide.

Explore the full profile